* Performance improvement plan working albeit at a snails pace
* No "large" cash cow coming soon from NIHL cases (if ever!)
* WTG escrow claim of 50mil will take several years to settle
* Class Action will take several years to settle
* Just enough cash to maintain liquidity
So,
* No big cash build up in FY17 to make any significant dent in Loans
* Re-financing of loans on the cards in FY18 i.e. performance improvement seem to be geared towards being able to re-finance (or perhaps dual listing)
i.e.
* No MAGIC BULLET
Half year results will be interesting to see if what was implied regarding Q1 performance is correct.
So, SGH share prices IMHO will be going sideways for a while and can't see any significant value creation until FY18 H1 results.
Just my opinion.
- Forums
- ASX - By Stock
- My take from AGM
SGH
sgh limited
Add to My Watchlist
2.87%
!
$52.52

* Performance improvement plan working albeit at a snails pace *...
-
-
- There are more pages in this discussion • 183 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$52.52 |
Change
-1.550(2.87%) |
Mkt cap ! $21.37B |
Open | High | Low | Value | Volume |
$51.37 | $53.58 | $51.11 | $35.93M | 685.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 95 | $52.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$52.69 | 433 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 95 | 52.440 |
3 | 1658 | 52.350 |
1 | 1669 | 52.290 |
1 | 1225 | 52.280 |
1 | 658 | 52.240 |
Price($) | Vol. | No. |
---|---|---|
52.690 | 433 | 2 |
52.730 | 1225 | 1 |
52.790 | 1225 | 1 |
52.860 | 1225 | 1 |
52.930 | 1225 | 1 |
Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
Featured News
SGH (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Dr. Steven Gourlay, CEO
Dr. Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online